JP2018521993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521993A5 JP2018521993A5 JP2017566000A JP2017566000A JP2018521993A5 JP 2018521993 A5 JP2018521993 A5 JP 2018521993A5 JP 2017566000 A JP2017566000 A JP 2017566000A JP 2017566000 A JP2017566000 A JP 2017566000A JP 2018521993 A5 JP2018521993 A5 JP 2018521993A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- day
- effective amount
- therapeutically effective
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180914P | 2015-06-17 | 2015-06-17 | |
| US62/180,914 | 2015-06-17 | ||
| PCT/US2016/038110 WO2016205671A1 (en) | 2015-06-17 | 2016-06-17 | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182192A Division JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182191A Division JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521993A JP2018521993A (ja) | 2018-08-09 |
| JP2018521993A5 true JP2018521993A5 (enExample) | 2019-07-04 |
| JP6599484B2 JP6599484B2 (ja) | 2019-10-30 |
Family
ID=57546446
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566000A Active JP6599484B2 (ja) | 2015-06-17 | 2016-06-17 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182191A Active JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182192A Active JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182191A Active JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182192A Active JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10471087B2 (enExample) |
| EP (3) | EP3505174B1 (enExample) |
| JP (3) | JP6599484B2 (enExample) |
| KR (3) | KR20180039624A (enExample) |
| CN (2) | CN116726035A (enExample) |
| AU (3) | AU2016280293B2 (enExample) |
| BR (2) | BR122020021913B1 (enExample) |
| CA (1) | CA2989653A1 (enExample) |
| CY (2) | CY1122605T1 (enExample) |
| DK (2) | DK3310362T3 (enExample) |
| ES (2) | ES2748556T3 (enExample) |
| HK (1) | HK1252133A1 (enExample) |
| HR (2) | HRP20191794T1 (enExample) |
| HU (2) | HUE046399T2 (enExample) |
| IL (3) | IL275256B2 (enExample) |
| LT (2) | LT3505174T (enExample) |
| MX (2) | MX2017016425A (enExample) |
| PL (2) | PL3310362T3 (enExample) |
| PT (2) | PT3505174T (enExample) |
| RS (2) | RS60572B1 (enExample) |
| RU (1) | RU2721492C2 (enExample) |
| SI (2) | SI3310362T1 (enExample) |
| SM (2) | SMT202000399T1 (enExample) |
| WO (1) | WO2016205671A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US10292996B2 (en) * | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| US10471087B2 (en) * | 2015-06-17 | 2019-11-12 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| CA3007286A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
| MX2019001799A (es) | 2016-08-24 | 2019-06-13 | Zogenix International Ltd | Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma. |
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| WO2019200340A1 (en) | 2018-04-12 | 2019-10-17 | Modis Therapeutics Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
| MX2020010994A (es) | 2018-04-18 | 2021-01-08 | Univ Columbia | Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial. |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| EP4017502A4 (en) * | 2019-08-19 | 2023-11-01 | Modis Therapeutics Inc. | POLYMORPH FORMS OF DEOXYCYTIDINE, COMPOSITIONS COMPRISING THEM AND USES |
| CN114340641B (zh) * | 2019-09-05 | 2025-04-04 | 米托瑞因博治疗股份有限公司 | 治疗线粒体dna缺失障碍 |
| WO2021188840A1 (en) * | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20220096514A1 (en) * | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
| WO2022145439A1 (ja) * | 2020-12-28 | 2022-07-07 | ヤマサ醤油株式会社 | 筋萎縮抑制剤及び筋萎縮を抑制させる方法 |
| CN117120060A (zh) * | 2021-03-26 | 2023-11-24 | 周格尼克斯-莫迪斯公司 | 含有嘌呤和嘧啶的水溶液及其用途 |
| EP4355336A4 (en) * | 2021-06-18 | 2025-05-07 | UCB Biosciences, Inc. | DEOXYNUCLEOSIDE PRODRUGS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE GROUPS |
| EP4554596A1 (en) * | 2022-07-12 | 2025-05-21 | UCB Biosciences, Inc. | Methods for increasing the bioavailability of nucleoside medicinal agents |
| WO2024206595A2 (en) * | 2023-03-30 | 2024-10-03 | The Trustees Of Columbia University In The City Of New York | Pharmacological therapy for mitochondrial dna depletion deletions syndrome involving mutations in the guk1 gene |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911237B (zh) * | 1998-08-10 | 2010-09-15 | 艾丹尼克斯(开曼)有限公司 | 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷 |
| KR100879559B1 (ko) * | 1999-02-23 | 2009-01-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 미토콘드리아 장애의 치료 또는 예방용 제약조성물 |
| US6596700B2 (en) * | 2000-05-26 | 2003-07-22 | Idenix Pharmaceuticals Inc. | Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides |
| WO2012125848A2 (en) * | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| PL3302499T3 (pl) * | 2015-06-05 | 2023-07-24 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Leczenie chorób mitochondrialnych |
| US10471087B2 (en) * | 2015-06-17 | 2019-11-12 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes |
-
2016
- 2016-06-17 US US15/736,092 patent/US10471087B2/en active Active
- 2016-06-17 LT LTEP19156021.8T patent/LT3505174T/lt unknown
- 2016-06-17 ES ES16812537T patent/ES2748556T3/es active Active
- 2016-06-17 CN CN202310757609.2A patent/CN116726035A/zh active Pending
- 2016-06-17 BR BR122020021913-0A patent/BR122020021913B1/pt active IP Right Grant
- 2016-06-17 CN CN201680045355.XA patent/CN107847512A/zh active Pending
- 2016-06-17 HU HUE16812537A patent/HUE046399T2/hu unknown
- 2016-06-17 RU RU2018101305A patent/RU2721492C2/ru active
- 2016-06-17 SM SM20200399T patent/SMT202000399T1/it unknown
- 2016-06-17 PL PL16812537T patent/PL3310362T3/pl unknown
- 2016-06-17 AU AU2016280293A patent/AU2016280293B2/en active Active
- 2016-06-17 CA CA2989653A patent/CA2989653A1/en active Pending
- 2016-06-17 BR BR112017027079-0A patent/BR112017027079B1/pt active IP Right Grant
- 2016-06-17 RS RS20200779A patent/RS60572B1/sr unknown
- 2016-06-17 KR KR1020187001496A patent/KR20180039624A/ko not_active Ceased
- 2016-06-17 KR KR1020257009842A patent/KR20250048602A/ko active Pending
- 2016-06-17 EP EP19156021.8A patent/EP3505174B1/en active Active
- 2016-06-17 EP EP16812537.5A patent/EP3310362B1/en active Active
- 2016-06-17 HR HRP20191794TT patent/HRP20191794T1/hr unknown
- 2016-06-17 HK HK18111524.2A patent/HK1252133A1/zh unknown
- 2016-06-17 KR KR1020227002790A patent/KR20220018623A/ko not_active Ceased
- 2016-06-17 PT PT191560218T patent/PT3505174T/pt unknown
- 2016-06-17 PL PL19156021T patent/PL3505174T3/pl unknown
- 2016-06-17 RS RS20191295A patent/RS59724B1/sr unknown
- 2016-06-17 MX MX2017016425A patent/MX2017016425A/es active IP Right Grant
- 2016-06-17 LT LT16812537T patent/LT3310362T/lt unknown
- 2016-06-17 SI SI201630439T patent/SI3310362T1/sl unknown
- 2016-06-17 IL IL275256A patent/IL275256B2/en unknown
- 2016-06-17 JP JP2017566000A patent/JP6599484B2/ja active Active
- 2016-06-17 DK DK16812537.5T patent/DK3310362T3/da active
- 2016-06-17 SI SI201630830T patent/SI3505174T1/sl unknown
- 2016-06-17 MX MX2020000269A patent/MX389016B/es unknown
- 2016-06-17 PT PT168125375T patent/PT3310362T/pt unknown
- 2016-06-17 SM SM20190571T patent/SMT201900571T1/it unknown
- 2016-06-17 HU HUE19156021A patent/HUE050678T2/hu unknown
- 2016-06-17 EP EP19178700.1A patent/EP3569236A1/en active Pending
- 2016-06-17 WO PCT/US2016/038110 patent/WO2016205671A1/en not_active Ceased
- 2016-06-17 DK DK19156021.8T patent/DK3505174T3/da active
- 2016-06-17 ES ES19156021T patent/ES2808148T3/es active Active
-
2017
- 2017-12-14 IL IL256331A patent/IL256331B/en active IP Right Grant
-
2019
- 2019-09-26 US US16/583,852 patent/US11110111B2/en active Active
- 2019-10-02 JP JP2019182191A patent/JP6675037B2/ja active Active
- 2019-10-02 JP JP2019182192A patent/JP7036782B2/ja active Active
- 2019-10-30 CY CY20191101127T patent/CY1122605T1/el unknown
-
2020
- 2020-06-09 IL IL275255A patent/IL275255B/en active IP Right Grant
- 2020-06-15 HR HRP20200949TT patent/HRP20200949T1/hr unknown
- 2020-06-17 AU AU2020204042A patent/AU2020204042B2/en active Active
- 2020-06-25 CY CY20201100578T patent/CY1123107T1/el unknown
-
2021
- 2021-04-28 US US17/242,822 patent/US11666592B2/en active Active
- 2021-10-11 AU AU2021250841A patent/AU2021250841B2/en active Active
-
2023
- 2023-04-24 US US18/138,432 patent/US12251392B2/en active Active
-
2025
- 2025-02-11 US US19/050,489 patent/US20250360154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521993A5 (enExample) | ||
| HRP20200949T1 (hr) | Deoksinukleozidna terapija bolesti uzrokovanih neurevnoteženim fondovima nukleotida, uključujući sindrome manjka mitohondrijske dna | |
| JP2016533379A5 (enExample) | ||
| JP5805071B2 (ja) | Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤 | |
| JP2017036288A5 (enExample) | ||
| ES2797900T3 (es) | Compuestos y combinaciones para el tratamiento del VIH | |
| JP2019525944A5 (enExample) | ||
| RU2017142555A (ru) | Способ стимуляции кишечной флоры | |
| JP2015078220A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2019505529A5 (enExample) | ||
| RU2018139655A (ru) | Бифидобактерии для увеличения безжировой массы тела | |
| JP2016539156A5 (enExample) | ||
| JP2017531673A5 (enExample) | ||
| JP2019038796A5 (enExample) | ||
| JP2021073257A5 (enExample) | ||
| Sey et al. | The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections | |
| NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
| JP2019038797A5 (enExample) | ||
| CN1615136A (zh) | 包含埃坡霉素和抗代谢物的组合 | |
| JP2016014051A5 (enExample) | ||
| Maciaszek | Muscles training for the stability of the spine | |
| WO2018175325A1 (en) | Hiv post-exposure prophylaxis | |
| Karthik | Yoghurt (LAB) as preventive method against COVID-19 | |
| Takahashi et al. | The novel 5-HT2B receptor antagonist, RQ-00310941, attenuates visceral hypersensitivity and abnormal defecation in rat models |